BEAM vs. SCHG

Last updated Jun 5, 2026

BEAM (Beam Therapeutics Inc.) is a stock, while SCHG (Schwab U.S. Large-Cap Growth ETF) is Large Cap Growth Equities fund tracking the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. Over the past 5 years, BEAM returned -16.85%/yr vs 15.67%/yr for SCHG. At a 0.42 correlation, their price movements are largely independent.

Performance

BEAM vs. SCHG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Beam Therapeutics Inc. (BEAM) and Schwab U.S. Large-Cap Growth ETF (SCHG). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BEAM achieves a 18.47% return, which is significantly higher than SCHG's 6.78% return.

BEAM

• 1D: 11.13%
• 1M: 13.63%
• YTD: 18.47%
• 6M: 13.59%
• 1Y: 91.49%
• 3Y*: -1.09%
• 5Y*: -16.85%
• 10Y*: —

SCHG

• 1D: 0.35%
• 1M: 4.73%
• YTD: 6.78%
• 6M: 6.01%
• 1Y: 24.63%
• 3Y*: 25.14%
• 5Y*: 15.67%
• 10Y*: 18.74%

*Multi-year figures are annualized to reflect compound growth (CAGR)

BEAM vs. SCHG - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
BEAM Beam Therapeutics Inc.	18.47%	11.77%	-8.89%	-30.40%	-50.92%	-2.39%	335.41%
SCHG Schwab U.S. Large-Cap Growth ETF	6.78%	17.50%	34.95%	50.10%	-31.80%	28.11%	29.97%

Correlation

The correlation between BEAM and SCHG is 0.36, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.36
Correlation (3Y) Calculated over the trailing 3-year period	0.32
Correlation (5Y) Calculated over the trailing 5-year period	0.45
Correlation (All Time) Calculated using the full available price history since Feb 7, 2020	0.42

The correlation between BEAM and SCHG shifts across timeframes, from 0.32 (3 years) to 0.45 (5 years), reflecting how their relationship changes across market environments.

Return for Risk

BEAM vs. SCHG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BEAM

BEAM Risk / Return Rank: 77
BEAM Sharpe Ratio Rank: 77
BEAM Sortino Ratio Rank: 78
BEAM Omega Ratio Rank: 72
BEAM Calmar Ratio Rank: 78
BEAM Martin Ratio Rank: 77

SCHG

SCHG Risk / Return Rank: 40
SCHG Sharpe Ratio Rank: 46
SCHG Sortino Ratio Rank: 44
SCHG Omega Ratio Rank: 45
SCHG Calmar Ratio Rank: 31
SCHG Martin Ratio Rank: 34

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BEAM vs. SCHG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Beam Therapeutics Inc. (BEAM) and Schwab U.S. Large-Cap Growth ETF (SCHG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BEAM	SCHG	Difference
Sharpe ratio: Return per unit of total volatility	1.23	1.60	-0.36
Sortino ratio: Return per unit of downside risk	2.20	2.18	+0.02
Omega ratio: Gain probability vs. loss probability	1.24	1.28	-0.04
Calmar ratio: Return relative to maximum drawdown	2.41	1.51	+0.90
Martin ratio: Return relative to average drawdown	5.21	5.04	+0.17
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BEAM vs. SCHG - Sharpe Ratio Comparison

The current BEAM Sharpe Ratio is 1.23, which is comparable to the SCHG Sharpe Ratio of 1.60. The chart below compares the historical Sharpe Ratios of BEAM and SCHG, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	BEAM	SCHG	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.23	1.60	-0.36
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.22	0.71	-0.93
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.87	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.12	0.85	-0.73

Drawdowns

BEAM vs. SCHG - Drawdown Comparison

The maximum BEAM drawdown since its inception was -89.12%, which is greater than SCHG's maximum drawdown of -34.59%. Use the drawdown chart below to compare losses from any high point for BEAM and SCHG.

Drawdown Indicators

	BEAM	SCHG	Difference
Max Drawdown Largest peak-to-trough decline	-89.12%	-34.59%	-54.53%
Max Drawdown (1Y) Largest decline over 1 year	-38.15%	-16.41%	-21.74%
Max Drawdown (3Y) Largest decline over 3 years	-67.74%	-23.39%	-44.35%
Max Drawdown (5Y) Largest decline over 5 years	-89.12%	-34.59%	-54.53%
Max Drawdown (10Y) Largest decline over 10 years	—	-34.59%	—
Current Drawdown Current decline from peak	-75.42%	-1.44%	-73.98%
Average Drawdown Average peak-to-trough decline	-59.82%	-5.20%	-54.62%
Ulcer Index Depth and duration of drawdowns from previous peaks	17.61%	4.90%	+12.71%

Volatility

BEAM vs. SCHG - Volatility Comparison

Beam Therapeutics Inc. (BEAM) has a higher volatility of 23.80% compared to Schwab U.S. Large-Cap Growth ETF (SCHG) at 3.61%. This indicates that BEAM's price experiences larger fluctuations and is considered to be riskier than SCHG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BEAM	SCHG	Difference
Volatility (1M) Calculated over the trailing 1-month period	23.80%	3.61%	+20.19%
Volatility (6M) Calculated over the trailing 6-month period	54.19%	11.62%	+42.57%
Volatility (1Y) Calculated over the trailing 1-year period	74.54%	15.49%	+59.05%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	75.85%	22.26%	+53.59%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	80.40%	21.55%	+58.85%

Dividends

BEAM vs. SCHG - Dividend Comparison

BEAM has not paid dividends to shareholders, while SCHG's dividend yield for the trailing twelve months is around 0.36%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BEAM Beam Therapeutics Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SCHG Schwab U.S. Large-Cap Growth ETF	0.36%	0.36%	0.39%	0.46%	0.55%	0.42%	0.52%	0.82%	1.27%	1.01%	1.04%	1.22%

Frequently Asked Questions

Can I hold both BEAM and SCHG in my portfolio?

BEAM and SCHG have a correlation of 0.36, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BEAM or SCHG?

BEAM has higher volatility (23.80%) compared to SCHG (3.61%). In terms of maximum drawdown, BEAM dropped -89.12% vs SCHG's -34.59%.

Which has better risk-adjusted returns?

SCHG currently has the higher Sharpe Ratio (1.60 vs 1.23), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.